All terms
CMS IDE Coverage (Category A & B)
Medicare coverage framework for items and services furnished in FDA-approved IDE studies — Category A (experimental) and Category B (non-experimental).
Reviewed by Christian Espinosa, Founder, Blue Goat CyberLast reviewed May 9, 2026
Definition
Under 42 CFR 405 Subpart B, CMS may cover routine costs and, for Category B IDEs, the device itself when furnished in an FDA-approved investigational device exemption study. FDA classifies an IDE device as Category A (experimental, novel risk-benefit profile not yet established) or Category B (non-experimental, generally a follow-on or substantial-equivalent design). Category B devices may be covered by Medicare; Category A devices generally are not, though routine costs may still be covered under the Clinical Trial Policy NCD 310.1. What the regulation says
42 CFR 405.201-405.215 (IDE coverage), NCD 310.1 (Clinical Trial Policy), and the joint FDA-CMS process for IDE classification at study approval.
What this means in practice
IDE coverage decisions can dramatically alter trial economics — a Category B classification with CMS coverage approval converts trial-device costs from sponsor-borne to payer-reimbursed. Common pitfalls
- •Assuming Category B classification automatically yields Medicare coverage — sites must still seek CMS approval and meet routine-cost criteria.
- •Failing to coordinate FDA IDE submission with the CMS coverage submission early.
Primary references
3 sourcesLink health: 3 verified· last checked 2026-05-09
CMS·1eCFR·1AdvaMed·1
- 1
CMS — Investigational Device Exemption StudiesVerifiedCMScms.gov
- 2
42 CFR 405 Subpart B — IDE CoverageVerifiedeCFRecfr.gov
- 3
AdvaMed - Payment & CoverageVerifiedAdvaMedadvamed.org
Inline markers like [1] jump to the matching reference above.